Degradation of Low Molecular Weight Uremic Solutes by Oral Delivery of Encapsulated Enzymes

ASAIO Journal

Volumn 50, Issue 3, 2004, Pages 253-260

  O'Loughlin, Jill A ^a,b   Bruder, Jan M ^a   Lysaght, Michael J ^a  

^a BROWN UNIVERSITY   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL ORGANS; ENCAPSULATION; ENZYMES; MOLECULAR WEIGHT; PATHOLOGY; TOXIC MATERIALS;

KIDNEY FAILURE; MICROCAPSULES;

BIOMEDICAL ENGINEERING;

ALGINIC ACID; CREATININASE; CREATININE; ION EXCHANGE RESIN; SORBENT; URATE OXIDASE; UREA; UREASE; URIC ACID;

ACUTE KIDNEY FAILURE; ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMICAL REACTION KINETICS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG CAPSULE; ENZYME DEGRADATION; ENZYME THERAPY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FAILURE; MICROCAPSULE; NONHUMAN; RAT; UREMIA;

ADMINISTRATION, ORAL; ALGINATES; ANIMALS; CAPSULES; CREATININE; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; ENZYMES, IMMOBILIZED; HYDROGELS; KIDNEY FAILURE, ACUTE; KIDNEY FAILURE, CHRONIC; KINETICS; MALE; RATS; RATS, SPRAGUE-DAWLEY; URATE OXIDASE; UREA; UREOHYDROLASES; URIC ACID;

EID: 2342552948     PISSN: 10582916     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MAT.0000123803.35535.71     Document Type: Article

References (32)

1. Galletti P, Colton C, Lysaght M: Artificial kidney, in Bronzino J (ed), The Biomedical Engineering Handbook, Boca Raton, FL: CRC Press, 1995, pp. 1898-1920.
2. Annemans L, Uyttebroeck A: Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. Support Care Cancer 11: 249-257, 2003.
3. Easton J, Noble S, Jarvis B: Rasburicase. Paediatr Drugs3: 433-437, 2001.
4. Navolanic P, Pui C, McCubrey J: Elitek-Rasburicase: An effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome. Leukemia 17: 499-514, 2003.
5. Lim F, Sun A: Microencapsulated islets as bioartificial endocrine pancreas. Science 210: 908-910, 1980.
6. Chang TMS: Hybrid artificial cells: microencapsulation of living cells. ASAIO Transactions 38: 128-130, 1992.
7. Uludag H, De Vos P, Tresco P: Technology of mammalian cell encapsulation. Adv Drug Deliv Rev 42: 29-64, 2000.
8. Gombotz W, Wee S: Protein release from alginate matrices. Adv Drug Deliv Rev 31: 267-285, 1998.
9. O'Loughlin J, Lysaght M: Release of albumin from alginate microspheres, in Proceedings of the 28th International Symposium on Controlled Release of Bioactive Materials #6042; June 23-27, 2001; San Diego, CA, p. 694.
10. Malchesky P, Nose Y: Biological reactors as renal substitutes. Artif Organs 3: 8-10, 1979.
11. Chang TMS: Kinetic studies of microencapsulated genetically engineered E. coli cells containing K. aerogenes gene for urea and ammonia removal. Biotechnol Bioeng 46: 621-626, 1995.
12. Setala K: Treating uremla with soil bacterial enzymes: Further developments. Clin Nephrol 11: 156-166, 1979.
13. O'Loughlin JA, Bruder JM, Lysaght MJ: Oral administration of biochemically active microcapsules to treat uremia: New insights into an old approach. J Biomater Sci Polym Ed (in press).
14. Gardner D, Kjellstrand C, Emmerling D. An orally administered microcapsule system for treating chronic renal failure patients. Appl Biochem Biotechnol 10: 27-40, 1984.
15. Wolfe E, Chang TMS: Orally ingested microencapsulated urease and an adsorbent, zirconium phosphate, to remove urea in kidney failure. Int J Artif Organs 10: 269-274, 1987.
16. Sparks R, Mason N, Lindan O: Removal of uremic waste metabolites from the intestinal tract by encapsulated carbon and oxidized starch. ASAIO Transactions 17: 229-235, 1971.
17. Mobley H: Microbial ureases: Significance, regulation, and molecular characterization. Microbiology Reviews 53: 85-108, 1989.
18. Dincturk H, Dunn A, Jones D: Recombinant pre-pro-Concanavalin A (jack bean) is stable but of low solubility. J Biosci 26: 635-640, 2001.
19. Miyagawa K, Sumida M, Nakao M: Purification, characterization, and application of an acid urease from Arthrobacter mobilis. J Biotechnol 68: 227-236, 1999.
20. Nakagawa S, Oda H, Anazawa H: High cell density cultivation and high recombinant protein production of Escherichia coli strain expressing uricase. Biosci Biotechnol Biochem 59: 2263-2267, 1995.
21. Bhosale S, Rao M, Deshpande V: Molecular and industrial aspects of glucose isomerase. Microbiology Reviews 60: 280-300, 1996.
22. Eolss Publishers Co. Ltd.: Encyclopedia of Life Support Systems. Available at: http://www.eolss.net. Accessed July 2003.
23. Murray J (ed): Mathematical Biology. New York: Springer-Verlag, 2002.
24. Zalups R: Reductions in renal mass and the nephropathy induced by mercury. Toxicol Appl Pharmacol 143: 366-379, 1997.
25. Hostetter T, Wilkes B: Renal circulatory and nephron function in experimental acute renal failure, in Brenner B, Lazarus JM (eds), Acute Renal Failure, Philadelphia, PA: W. B. Saunders Company, 1983, pp. 99-115.
26. Wilson D, Thiel G, Arce M, Oken D: Glycerol induced hemoglobinuric acute renal failure in the rat. Nephron 4: 337-355, 1967.
27. Nelson D, Cox M (eds): Lehninger Principles of Biochemistry. New York: Worth Publishers, Inc., 2000.
28. Lysaght M, O'Loughlin J: Demographic scope and economic magnitude of contemporary organ replacement therapies. ASAIO Transactions 46: 515-521, 2000.
29. Bloembergen W: Outcome of end stage renal disease therapies, in Greenberg A (ed), Primer on Kidney Diseases, San Diego, CA: Academic Press, 1998, pp. 422-428.
30. Neu S, Kjellstrand C: Stopping long-term dialysis. An empirical study of withdrawal of life-supporting treatment. N Engl J Med 314: 14-20, 1986.
31. Gautam S, Humes HD: Renal replacement devices: The development of the bioartificial kidney, in Kuhtreiber W (ed), Cell Encapsulation Technology and Therapeutics New York: Springer-Verlag, 1999, pp. 287-299.
32. United Network for Organ Sharing: United Network for Organ Sharing Web site. Available at: www.unos.org. Accessed June 2003.